DYAI Dyadic International, Inc.
0.4565USD+0.71%Mkt Cap: 18.29M $P/E: —1d ago
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Produ…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.99BUSDP/E 14.5
$22.27BUSDP/E 30.7
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 Dyadic International (DYAI) Q2 2026 Earnings Call Transcript Company advances commercialization with initial product shipments and distribution deals. | ||
 Dyadic International, Inc. Q2 2026 Earnings Call Summary Moby summary of Dyadic International, Inc.'s Q2 2026 earnings call | ||
Dyadic International Inc (DYAI) (Q2 2026) Earnings Call Highlights: Revenue Surges 52% as ... Despite a 52% revenue increase and significant productivity gains, Dyadic International Inc (DYAI) faces a going concern uncertainty, requiring additional capital within the next 12 months. | ||